In addition, preclinical studies have demonstrated the anti-inflammatory effects of SGLT2 inhibitors empagliflozin and dapagliflozin in association with a reduction in albuminuria and renal fibrosis in DKD [174,175]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.